Anika Reports Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.

BEDFORD, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has granted:

• on March 1, 2022 to three newly hired non-executive employees, (a) non-statutory stock options (“OSN”) for the exercise of an aggregate of 9,529 common shares at an exercise price per share of $31.50, which is equal to the closing price of common stock on the Nasdaq Global Select Market (the “Closing Price”) on the date of grant, and (b) restricted stock units ( “RSU”) covering a total of 4,280 ordinary shares; and
• on March 11, 2022 to a newly hired fourth non-executive employee, (a) ONS for the exercise of 8,029 common shares at an exercise price per share of $25.58, which equaled the closing price on the date grant, (b) NSO for the exercise of 8,535 common shares at an exercise price per share of $28.14, which was equal to 110% of the closing price on the grant date, and (c ) PSUs covering 7,372 common shares.

Of the shares covered by the NSOs and PSUs, one-third will vest on each of the first three anniversaries of the respective grant dates, in each case so long as the beneficiary provides continuous service to Anika up to the relevant vesting date. . Unless terminated earlier in accordance with their terms, the NSOs will expire on the tenth anniversary of their respective grant dates. The awards are otherwise subject to the terms of the respective equity award agreements approved by Anika.

Each of the awards was made in accordance with Anika’s 2021 Incentive Plan, was approved by the Compensation Committee of the Board of Directors or pursuant to a delegation of authority by the Board and, in accordance with the Rule of listing on Nasdaq 5635(c)(4), was made as a material inducement to the recipient’s acceptance of employment with Anika as part of the recipient’s employment compensation. The 2021 incentive plan has not been submitted for shareholder approval.

About AnikaAnika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and achieves significant advances in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. We focus on high-potential areas in orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair in sports medicine, and bone-preserving joint technologies, and our products are effectively delivered to major care sites, including ambulatory surgery centers. Anika’s global operations are based out of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

For investor inquiries:Anika Therapeutics, Inc.Mark Namaroff, 781-457-9287Vice President, Investor Relations, ESG and Corporate Communications[email protected]

Source: Anika Therapeutics Inc.